Andreotti AH, Bunnell SC, Feng S, Berg LJ, Schreiber SL. Regulatory intramolecular association in a tyrosine kinase of the Tec family. Nature. 1997;385(6611):93-7. doi:10.1038/385093a0
Luo T, Masson K, Jaffe JD, et al. STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012;109(8):2860-5. doi:10.1073/pnas.1120589109
Weïwer M, Bittker JA, Lewis TA, et al. Development of small-molecule probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem Lett. 2012;22(4):1822-6. doi:10.1016/j.bmcl.2011.09.047
Ong SE, Li X, Schenone M, Schreiber SL, Carr SA. Identifying cellular targets of small-molecule probes and drugs with biochemical enrichment and SILAC. Methods Mol Biol. 2012;803:129-40. doi:10.1007/978-1-61779-364-6_9
Belshaw PJ, Spencer DM, Crabtree GR, Schreiber SL. Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization. Chem Biol. 1996;3(9):731-8.
Wilson AJ, Holson E, Wagner F, et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther. 2011;12(6):484-93. doi:10.4161/cbt.12.6.15956
Luan S, Kudla J, Gruissem W, Schreiber SL. Molecular characterization of a FKBP-type immunophilin from higher plants. Proc Natl Acad Sci U S A. 1996;93(14):6964-9.
Cimprich KA, Shin TB, Keith CT, Schreiber SL. cDNA cloning and gene mapping of a candidate human cell cycle checkpoint protein. Proc Natl Acad Sci U S A. 1996;93(7):2850-5.
O’Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol. 2010;17(10):1218-25. doi:10.1038/nsmb.1897
Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci U S A. 2010;107(28):12617-22. doi:10.1073/pnas.1006774107